国: イスラエル
言語: 英語
ソース: Ministry of Health
SITAGLIPTIN AS HYDROCHLORIDE
UNIPHARM TRADING LTD, ISRAEL
A10BH01
FILM COATED TABLETS
SITAGLIPTIN AS HYDROCHLORIDE 100 MG
PER OS
Required
LABORATORIOS LICONSA S.A., SPAIN
SITAGLIPTIN
SITAR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes melitus. Important limitations of use: SITAR should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis as it would not be effective in these settings. SITAR has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using SITAR.
2023-05-04
PATIENT PACKAGE INSERT IN ACCORDANCE WITH THE PHARMACISTS’ REGULATIONS )PREPARATIONS( – 1986 The medicine is dispensed with a doctor’s prescription only Sitar 25 Film-coated tablets Each film-coated tablet contains: Sitagliptin )as hydrochloride( 25 mg Sitar 50 Film-coated tablets Each film-coated tablet contains: Sitagliptin )as hydrochloride( 50 mg Sitar 100 Film-coated tablets Each film-coated tablet contains: Sitagliptin )as hydrochloride( 100 mg For a list of inactive ingredients and allergens in the preparation, see section 6 “Further information”. See also section 2.8 “Important information about some of the ingredients of the medicine”. Read this leaflet carefully in its entirety before using the medicine. • This leaflet contains concise information about the medicine. If you have further questions, refer to the doctor or pharmacist. • This medicine has been prescribed for you. Do not pass it on to others. It may harm them even if it seems to you that their medical condition is similar. • This medicine is not intended for administration to children and adolescents under 18 years of age. 1. WHAT IS SITAR INTENDED FOR? Sitar is indicated as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus. Important limitations of use: Sitar should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, and will not be effective in these situations. Sitar has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at high risk for the development of pancreatitis while using Sitar. Therapeutic group: DPP-4 enzyme inhibitors. Sitar belongs to a group of medicines called DPP-4 inhibitors )dipeptidyl peptidase-4 inhibitors(, which are taken orally, and lower blood sugar levels in adult patients with type 2 diabetes mellitus. 2. BEFORE USING SITAR 2.1 Do not use Sitar if: - you are sensitive )allergic( to any of the ingredients of Sitar )see section 6 完全なドキュメントを読む